机构地区:[1]School of Clinical Medicine,Chengdu Medical College,Chengdu 610000,Sichuan Province,China [2]Department of Neuroscience,College of Veterinary Medicine and Life Sciences,City University of Hong Kong,Hong Kong,China [3]Department of Geriatrics,Sichuan Provincial People’s Hospital,University of Electronic Science and Technology of China,Chengdu 610000,Sichuan Province,China [4]Department of Geriatrics,Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital,Chengdu 610072,Sichuan Province,China
出 处:《World Journal of Clinical Cases》2022年第30期10984-10996,共13页世界临床病例杂志
基 金:Supported by the Key Research and Development Projects of Sichuan Science and Technology Department,No.22ZDYF1691,No.2018FZ0062,and No.2020YFS0410。
摘 要:BACKGROUND Liver cirrhosis(LC)is currently the 11^(th) most common cause of death and 15^(th) cause of morbidity globally.The treatment of LC is mainly aimed at etiological intervention,lifestyle intervention,prevention and treatment of complications and nutritional treatment.Nutritional treatment of LC mainly includes increasing dietary intake,food intake time and branched-chain amino acids(BCAAs).Despite the recommendation of BCAAs in some guidelines,adverse effects have been reported in studies so the efficacy and safety of BCAAs remain controversial.Currently,BCAAs have been widely used in chronic liver disease,while the summary of the effect of BCAAs on long-term prognosis is rare.AIM To determine the effects of BCAAs in patients with LC.METHODS The PubMed,Cochrane Library,Embase and Web of Science databases were searched.The retrieval deadline was 1 October 2021 and there were no language restrictions set in the retrieval.The study was performed in strict accordance with the inclusion and exclusion criteria.Nine studies were finally included.The primary outcome was complications of LC.The secondary outcomes were nutritional status and liver function.This meta-analysis used the Review Manager,version 5 statistical package(Cochrane Collaboration,Oxford,England)for analysis.RESULTS The analysis included nine studies that consisted of 1080 patients(554 in the BCAA groups and526 in the control groups).The nine studies were randomized control trials(RCTs).The quality of the studies was assessed using the risk of bias method recommended by the Cochrane Collaboration.BCAAs reduced the rate of complications in LC patients[Risk ratio:0.70,95%confidence interval(CI):0.56-0.88,P=0.002]and improved patients’albumin levels[std mean difference SMD:0.26,95%CI:0.12-0.40,P=0.0002].Meanwhile,BCAAs significantly ameliorated the levels of alanine transaminase(SMD:-2.03,95%CI:-2.52 to-1.53,P<0.00001)and aspartate aminotransferase(SMD:-1.8,95%CI:-2.14 to-1.46,P<0.00001).Meanwhile,glucose in the LC was significantly increased in
关 键 词:Liver cirrhosis Branched-chain amino acids COMPLICATIONS NUTRITION Liver function GLUCOSE
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...